Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 13/20 | 0.65 |
| ▸ | MME | P08473 | 8/20 | 0.62 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197781 | 0.91 | MMEL1 (0.54) | MMEL1MMEACE | |
| SCHEMBL8580410 | 0.87 | MMEL1 (0.57) | MMEL1MMEACE | |
| SCHEMBL18672742 | 0.87 | MME (0.67) | MMEL1MMEACE | |
| SCHEMBL12939775 | 0.87 | MME (0.67) | MMEL1MMEACE | |
| SCHEMBL18672741 | 0.87 | MME (0.67) | MMEL1MMEACE | |
| SCHEMBL12939766 | 0.87 | MME (0.67) | MMEL1MMEACE | |
| SCHEMBL16132542 | 0.81 | MMEL1 (0.64) | MMEL1MMEACE | |
| SCHEMBL2870028 | 0.79 | MMEL1 (0.68) | MMEL1MMEACE | |
| SCHEMBL2870535 | 0.79 | MMEL1 (0.68) | MMEL1MMEACE | |
| SCHEMBL2870057 | 0.79 | MMEL1 (0.82) | MMEL1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | MMEL1 118/4885MME 3/4885ACE 92/4885 |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | MMEL1 299/4885MME 1/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.